{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T13:11:21Z","timestamp":1779196281730,"version":"3.51.4"},"reference-count":16,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T00:00:00Z","timestamp":1642723200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Multiple myeloma (MM) is the second most common hematological malignancy, accounting for 1% of all cancers, with median age of diagnosis between 66\u201370 years. MM remains incurable despite advances in treatment over time. Lenalidomide is an important medication used in induction therapy for MM and is also used for maintenance therapy for standard risk patients. With its increasing use, data is emerging about its use being associated with increased risk of secondary primary malignancies (SPM), especially when used as maintenance therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case series<\/jats:title>\n                    <jats:p>In this case series, we describe three patients with refractory MM treated with lenalidomide maintenance who later developed sALL. All had a common presentation of pancytopenia. They developed cytopenias while being on lenalidomide which was refractory to lenalidomide cessation, prompting bone marrow biopsy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Management and outcome<\/jats:title>\n                    <jats:p>Lenalidomide was subsequently stopped, and patients were treated for secondary B-ALL. However, all passed away either due to relapse of disease or complications arising from treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>The mechanism of lenalidomide associated SPMs is not well understood however its incidence is well documented. At least 13 cases of ALL (predominantly B-cell ALL) following Immunomodulator imide drugs (IMiDs) have been reported in literature. An analysis of a larger cohort of patients is required to determine causality of lenalidomide with sALL. However, benefits of maintenance lenalidomide in patients with MM outweighs the risk of developing SPMs. Albeit persistent pancytopenia on lenalidomide therapy should be evaluated with bone marrow biopsy since it could be caused by secondary B -cell ALL.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552211073967","type":"journal-article","created":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T09:39:00Z","timestamp":1642757940000},"page":"1214-1217","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":5,"title":["Three Cases of Lenalidomide Therapy for Multiple Myeloma and Subsequent Development of Secondary B-ALL"],"prefix":"10.1177","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7981-6528","authenticated-orcid":false,"given":"Urwat Til","family":"Vusqa","sequence":"first","affiliation":[{"name":"Allegheny Health Network"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zena","family":"Chahine","sequence":"additional","affiliation":[{"name":"University of Kentucky"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9210-3338","authenticated-orcid":false,"given":"Palash","family":"Asawa","sequence":"additional","affiliation":[{"name":"Allegheny Health Network"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santhosh","family":"Sadashiv","sequence":"additional","affiliation":[{"name":"Allegheny Health Network Cancer Institute, Division of Hematology and Cellular Therapy, Pittsburgh, PA, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0271-4798","authenticated-orcid":false,"given":"Yazan","family":"Samhouri","sequence":"additional","affiliation":[{"name":"Allegheny Health Network Cancer Institute, Division of Hematology and Cellular Therapy, Pittsburgh, PA, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Lister","sequence":"additional","affiliation":[{"name":"Allegheny Health Network Cancer Institute, Division of Hematology and Cellular Therapy, Pittsburgh, PA, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2022,1,21]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.soncn.2017.05.012"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2016.11.004"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_159244"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24402"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-2-36"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.114"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.799"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30140-0"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1114138"},{"key":"e_1_3_2_11_2","first-page":"553","article-title":"Lenalidomide: a brief review of its therapeutic potential in myelodysplastic syndromes","volume":"3","author":"Giagounidis AA","year":"2007","unstructured":"Giagounidis AA, Germing U, Haase S, et al., Lenalidomide: a brief review of its therapeutic potential in myelodysplastic syndromes. Ther Clin Risk Manag 2007; 3: 553\u2013562.","journal-title":"Ther Clin Risk Manag"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcna.2017.06.010"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-08-373514"},{"key":"e_1_3_2_15_2","first-page":"9052314","article-title":"Acute lymphoblastic leukemia following lenalidomide maintenance for multiple myeloma: two cases with unexpected presentation and good prognostic features","volume":"2018","author":"Khan AM","year":"2018","unstructured":"Khan AM, Muzaffar J, Murthy H, et al. Acute lymphoblastic leukemia following lenalidomide maintenance for multiple myeloma: two cases with unexpected presentation and good prognostic features. Case Rep Hematol 2018; 2018: 9052314.","journal-title":"Case Rep Hematol"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature05690"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1244917"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552211073967","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552211073967","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552211073967","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T12:37:38Z","timestamp":1779194258000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552211073967"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,21]]},"references-count":16,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["10.1177\/10781552211073967"],"URL":"https:\/\/doi.org\/10.1177\/10781552211073967","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,21]]}}}